Personalised tumour-detecting cells from adult skin cells have been used to shrink brain tumours in mice by up to 5%, scientists have revealed. While the strategy has not yet been fully tested in people, it could in the future give doctors the ability to develop a custom treatment for certain cancer types.
Genomics will change what patients expect from their provider, as well as change how physicians treat them. Before this happens, education on both sides is needed. This month we look at some of the big talking points.
Scientists from the University of Pennsylvania have created a test using gene-editing tools such as CRISPR to identify a gene variant responsible for severe hypertrophic cardiomyopathy (SHC). SHC is an often-familial disease which thickens heart walls and is linked to a variant in the TNNT2 gene.
An innovative gene therapy treatment for Parkinson’s seems to relieve symptoms by rewriting the brain, scientists have found. Following the success of the therapy study, the researchers are planning a larger trial to start at the end of 2019.
Time to pop the champagne – 100,000 genomes have been reached. Well done Genomics England!
A universal test which can detect traces of any cancer in a patient’s bloodstream in ten minutes has been developed by scientists from the University of Queensland. As it stands the test has a sensitivity of 90%, so is able to detect 90 in 100 cases of cancer.
APP, the gene responsible for making beta-amyloid in the brain, may be able to reshuffle its own DNA, scientists from Sanford Burnham Prebys Medical Discovery Institute in California have claimed. This development could explain why most drugs to treat Alzheimer’s, which are designed to remove beta-amyloid protein build-ups in the brain, have proven ineffective in clinical trials.
Machine learning can help healthcare workers predict whether patients may require emergency hospital admission, new study finds
STAT news have put together a great article assessing the need for health care systems to get on top of the payment issue quickly. Give it a read!
The Novartis CAR-T cell therapy, Kymriah (tisagenlecleucel), will be made available to patients under the age of 25 via the Cancer Drugs Fund.
Scientists have found a cause for the frequent and damaging events in cancer cells’ genetic material where sections of individual chromosomes were broken at a number of points and reassembled wrongly, so entire sections were missing and others were duplicated or incorporated in a wrong orientation.
A minuscule, biodegradable scaffold has been created to transplant stem cells and deliver drugs within the body, the Nature Communications journal has reported, which could help with treatments for Alzheimer’s and Parkinson’s diseases, as well as aging brain degeneration and spinal cord injuries.
We spoke to Dr. David R. Hillyard MD, Chair and Medical Director of Molecular Infectious Diseases at ARUP Laboratories, about his work within the realm of infectious diseases and the increasing role of molecular diagnostics in combating pathogens.